Therapies and surgical treatment of the posterior segment
Joined May 2013
- Tweets 3,801
- Following 436
- Followers 3,629
- Likes 617
2,783 Photos and videos
Amazing meeting going on in Las Vegas! Look for our coverage of Clinical Trials at the Summit next week.
75
Reflecting on Retina World Congress 2026 ποΈ
In this video snippet, Ashkan M. Abbey, MD, reviews the evolving Duravyu (EYP-1901) clinical program from EyePoint Pharmaceuticals, including the upcoming pivotal phase 3 milestones in wet AMD.
Watch in full π
ow.ly/m1Tt50Z53H5
1
215
We're excited to partner with OIS Retina on July 14 in Montreal. With innovative companies presenting, expert panels, and unmatched networking, this is a retina event you won't want to miss. Learn more and register today.
ois.net/retina-innovation-suβ¦
33
Could retinal implants change the future of geographic atrophy care?
A new Clinical Trial Download explores the PRIMA photovoltaic implant system and early PRIMAvera trial data showing promising potential for restoring central vision in advanced GA: ow.ly/uRsU50Z54wb
1
62
Arshad M. Khanani, MD, previews this year's Clinical Trials at the Summit meeting in Las Vegas.
retinalphysician.com/issues/β¦
#CTS2026 #Retina #ClinicalTrials
1
3
66
ποΈ Telemedicine is reshaping retinal care.
In a new article, Nnamdi Elem Okore, OD, discusses how teleretinal screening and AI-assisted imaging could improve access, equity, and efficiency in diabetic retinopathy care π
Read more: ow.ly/K5Yt50Z099I
#Retina
83
#RetinaWorldCongress Katherine E. Talcott, shared research linking BRVO and CRVO with increased risks of stroke, heart attack, and carotid disease, highlighting how retinal findings may reveal important clues about systemic health.
Read more: ow.ly/UWCJ50Z2AiJ
#Retina
1
126
Can gene therapy finally reduce the injection burden in wet AMD?
At #RetinaWorldCongress, David Eichenbaum, reviewed emerging phase 3 data on intravitreal gene therapies designed to deliver long-term anti-VEGF expression after a single treatment.
Read on ow.ly/Q4sY50Z1viM
2
113
At #ARVO2026, Cecilia S. Lee, MD, MS, and Aaron Y. Lee, MD, MSCI, explored the evolution from paper charts to AI-driven precision health, and the mentors and collaborations that shaped their journey.
Read more π
ow.ly/yRQj50Z2zBE
#Ophthalmology
83
π New insights into steroid strategies for diabetic macular edema.
Ashish Sharma & Baruch D. Kuppermann discuss how corticosteroids are being incorporated into DME management, from patient selection to dosing and safety considerations ποΈ
ow.ly/v7YA50Z08V9
#Retina
1
95
ποΈβπ¨οΈ At #ARVO2026, NEI Director Michael Chiang, MD, highlighted new opportunities for vision research through AI, precision medicine, collaboration & data sharing π
Ophthalmology researchers are being encouraged to help shape the future of innovation: retinalphysician.com/issues/β¦
82
At #RetinaWorldCongress, Sunir J. Garg, MD, FACS, shared practical strategies to help retina specialists reduce neck, back, wrist, and shoulder strain through better posture, workspace setup, and OR positioning.
Read more π
ow.ly/cUbk50Z2zlc
#Ophthalmology #Retina
99
ποΈ New research from Abraham Olvera-Barrios, MD, PhD, and Cathy Egan, FRANZCO, explores how automated retinal imaging systems could improve detection, reduce workload, and expand access to care worldwide π
Read more: ow.ly/v4gP50Z08Bc
#Ophthalmology
1
94
Could GLP-1 therapies impact retinal disease risk? π
New evidence reviewed at Retina World Congress suggests some retinal safety signals may be real, especially in patients with preexisting diabetic retinopathy.
Read more: ow.ly/5A2z50Z1vcj
#Ophthalmology #GLP1 #Retina
1
112
π¨ #ARVO2026: Phase 2 Alluvium data showed IL-6 inhibitor vamikibart improved visual acuity and retinal anatomy in treatment-naΓ―ve DME patients.
The findings support further exploration of combining antiβIL-6 and anti-VEGF approaches in #retina care.
ow.ly/LxAs50Z1HB1
2
104
π¨ FDA updates from #RetinaWorldCongress 2026 could reshape retina drug development.
William M. Boyd discussed:
ποΈ AI-assisted FDA review
ποΈ Real-time clinical trial monitoring
ποΈ Faster approval pathways
ποΈ Rare retinal disease initiatives
Read more: ow.ly/CSYr50Z1uOY
1
85
Could retinal biomarkers help personalize DME treatment? ποΈβ¨
This article explores how OCT and OCTA imaging may help predict treatment response, guide therapy selection, and improve outcomes in diabetic macular edema.
Read more: ow.ly/Z6SK50YYVI9
#Retina
2
92
How do we move ophthalmic AI from concept to clinical reality? ποΈ
At Focus A-Eye Summit, clinicians & industry leaders came together to discuss barriers to AI adoption and what it will take to move from innovation to practical clinical use.
Read more: ow.ly/FxUg50YYVmW
1
69
at #ARVO2026, Baruch D. Kuppermann, MD, PhD, presented findings from the DME AWARE Delphi Study highlighting key unmet needs in DME management, including earlier intervention, noninvasive therapies, and improved treatment adherence.
π Read more: ow.ly/5t3b50YVXBy
2
68
Could AI help reduce screen failures in geographic atrophy clinical trials?
Data presented at #ARVO2026 showed a clinic-based AI tool reduced screen failure rates and demonstrated close agreement with manual measurements during GA trial prescreening.
π ow.ly/rCHF50YVXkz
1
95